STOCK TITAN
  1. Home
  2. News
  3. TCRX

TScan Therapeutics, Inc. - TCRX STOCK NEWS

Welcome to our dedicated page for TScan Therapeutics news (Ticker: TCRX), a resource for investors and traders seeking the latest updates and insights on TScan Therapeutics stock.

TScan Therapeutics, Inc. (NASDAQ: TCRX) is a pioneering biopharmaceutical company focused on developing advanced T-cell receptor (TCR) engineered T cell therapies (TCR-T) aimed at treating cancer. Specializing in harnessing novel T cell systems, TScan is at the forefront of extending the promise of immunotherapy to patients with hematologic malignancies and solid tumors.

The company's leading therapies, TSC-100 and TSC-101, are designed to eliminate residual leukemia and prevent relapse in patients with blood cancers such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplantation. These liquid tumor TCR-T therapy candidates are currently in development, reflecting TScan's commitment to improving patient outcomes.

TScan is also developing multiplexed TCR-T therapy candidates for treating various solid tumors, showcasing the company's versatility and innovative approach in the immunotherapy landscape. Recent recognition includes the RMAT designation granted for both TSC-100 and TSC-101, highlighting their potential significance in cancer treatment.

In addition to its groundbreaking therapeutic developments, TScan Therapeutics maintains strong partnerships and a robust financial foundation. The company frequently updates its stakeholders through transparent communication and investor relations, ensuring that all relevant developments and milestones are promptly shared.

For the latest news and updates, you can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com. Further inquiries can also be directed to Joyce Allaire, Managing Director at LifeSci Advisors, LLC, at 617-435-6602 or jallaire@lifesciadvisors.com.

News

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) provides an update on its solid tumor and heme malignancies clinical programs. Over 40 solid tumor patients completed biomarker testing, with 60% qualifying for TCR-T therapy. All heme program patients remain relapse-free. The company plans to dose the first three solid tumor patients in early May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
none
-
News

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

Rhea-AI Summary
TScan Therapeutics appoints Dr. Chrystal Louis as Chief Medical Officer, bringing extensive experience in hematology and oncology drug development. Dr. Louis will lead the clinical and commercial development of TCR-engineered T cell therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.53%
Tags
management
-
News

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will present at the 23rd Annual Needham Virtual Healthcare Conference to discuss their TCR-engineered T cell therapies for cancer treatment. The presentation will be available via webcast on their website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.11%
Tags
conferences
News

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) reports updated data from Phase 1 study showing positive outcomes for heme malignancies treatment. They also announced the clearance of two additional INDs for their Solid Tumor Program. Financially, the company has strong cash reserves to fund operations into 2026 and has seen revenue growth in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
earnings
-
News

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
TScan Therapeutics, Inc. (TCRX) will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference. The event will be held on March 6, 2024, at 9:10 a.m. Eastern Time in Boston. A webcast of the panel discussion will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.03%
Tags
conferences
-
News

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Rhea-AI Summary
TScan Therapeutics, Inc. presents positive data at the 2024 Tandem Meetings, showing high success rates in preventing relapse in patients with AML, MDS, and ALL using TSC-100 and TSC-101. All treated patients achieved complete donor chimerism, with no relapses to date. The company will host a virtual KOL event to discuss the data further.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
clinical trial
News

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) will host a virtual KOL event to discuss updated results from its Phase 1 heme malignancies study and highlights from its oral presentation at the 2024 Tandem Meetings. The event will focus on TSC-100 and TSC-101 in treating residual disease and preventing relapse in patients with AML, MDS, or ALL. The Company will also discuss initial data from a clinical trial on donor chimerism and relapse risk.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
conferences clinical trial
-
News

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings over a decade of experience in clinical development across the pharmaceutical and biotechnology industry. TScan remains on track to dose the first patient in the Phase 1 solid tumor study in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
management clinical trial
-
News

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) appoints Jason A. Amello as Chief Financial Officer, bringing nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry. The company is making significant progress across both heme and solid tumor programs, with recent positive initial data from its Phase 1 heme program, INDs clearance for the use of multiple TCRs in solid tumor clinical trials, and a strong balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
management
News

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Rhea-AI Summary
TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the acceptance of an abstract for oral presentation at the Best Abstracts session of the upcoming Tandem Meetings. The presentation will highlight initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, designed to treat residual disease and prevent relapse following hematopoietic cell transplantation in patients with AML, MDS, or ALL. The abstract was selected to receive a Best Abstracts Award, and the presentation details include the title, authors, abstract ID number, session, date & time, and location. A copy of the presentation materials will be added to the Company’s Investor Relations website at ir.tscan.com once presentations have concluded.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
none

FAQ

What is the current stock price of TScan Therapeutics (TCRX)?

The current stock price of TScan Therapeutics (TCRX) is $2.91 as of December 24, 2024.

What is the market cap of TScan Therapeutics (TCRX)?

The market cap of TScan Therapeutics (TCRX) is approximately 155.3M.

What is TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. is a biopharmaceutical company specializing in T-cell receptor (TCR) engineered T cell therapies (TCR-T) for cancer treatment.

What are TScan's leading therapy candidates?

TScan's leading therapy candidates are TSC-100 and TSC-101, aimed at treating blood cancers like AML and ALL.

What recent recognition has TScan's therapies received?

TSC-100 and TSC-101 have been granted RMAT designation for their potential in treating AML, ALL, and MDS.

What types of cancer does TScan focus on?

TScan focuses on hematologic malignancies and various solid tumors.

How does TScan aim to improve cancer treatment?

TScan aims to improve cancer treatment by developing TCR-T therapies that target and eliminate residual cancer cells, reducing the risk of relapse.

How can I contact TScan's Investor Relations?

You can contact Heather Savelle, VP of Investor Relations, at 857-399-9840 or via email at hsavelle@tscan.com.

Where can I get the latest updates about TScan?

Latest updates and news can be found by contacting TScan's Investor Relations or visiting their official website.

What is the stock symbol for TScan Therapeutics, Inc.?

TScan Therapeutics, Inc. trades on NASDAQ under the symbol TCRX.

Who are the key contacts for media inquiries at TScan?

For media inquiries, you can contact Heather Savelle at TScan Therapeutics or Maghan Meyers at Argot Partners.

What are TScan's goals in immunotherapy?

TScan aims to extend the promise of immunotherapy through innovative TCR-T cell therapies that offer new hope to cancer patients.

Stock TCRX logo
TScan Therapeutics, Inc.

Nasdaq:TCRX

TCRX Rankings

#4089 Ranked by Market Cap
N/A Ranked by Dividends

TCRX Stock Data

155.31M
52.81M
0.82%
86%
4.3%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WALTHAM